Fundraising Fox

TNF Pharmaceuticals

New York, US · Founded 2023 · Delaware corporation

TNF Pharmaceuticals is a clinical-stage biopharma company developing therapies for autoimmune and inflammatory diseases, with lead candidates including MYMD-1, an oral TNF-alpha inhibitor, and Supera-CBD, a synthetic cannabidiol analog.

BiotechCrypto & Web3Deep TechHardwareHealthtechLongevity

Founders & leadership

IR
Ian RhodesChief Financial Officer
MG
Mitchell GlassChief Medical Officer
JSJoshua Silverman
Joshua SilvermanExecutive Chairman
RA
Raymond AkersSecretary
JG
John GormallyChief Executive Officer
GR
Gary RauchVP, Finance and Treasurer

Board

CS
Christopher SchreiberBoard director
BK
Brandon KnoxBoard director
TK
Thomas KnoxNon-Executive Chairman
BB
Bruce BernsteinBoard director
SF
Stephen FrisciaBoard director
BJ
Bill J. WhiteBoard director

Reported raises · per SEC filings

Form D private placements

$71.3M disclosed across 8 of 10 rounds · 2017–2025

▶$7MraisedSep 2025 · 12 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher SchreiberDirector
  • Bruce BernsteinDirector
  • Ian RhodesExecutive Officer
  • Mitchell GlassExecutive Officer, Director
  • Stephen FrisciaDirector
  • Bill J. WhiteDirector
  • Joshua SilvermanExecutive Officer, Director
Offering amount
$7M
Amount sold
$7M
Sales commissions
$630K
Placement agents
GP Nurmenkari Inc., Rodman & Renshaw, LLC, H.C. Wainwright & Co., LLC
First sale
Sep 2025
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.2MraisedMay 2024 · 5 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Chris ChapmanExecutive Officer
  • Bill J. WhiteDirector
  • Ian RhodesExecutive Officer
  • Jude UzonwanneDirector
  • Craig EagleDirector
  • Joshua SilvermanDirector
  • Christopher SchreiberDirector
  • Mitchell GlassDirector
Offering amount
$15.2M
Amount sold
$15.2M
Sales commissions
$303K
Placement agents
Palladium Capital Group, LLC, GP Nurmenkari Inc.
First sale
May 2024
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$26.9MraisedMay 2024 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Ian RhodesExecutive Officer
  • Chris ChapmanExecutive Officer
  • Christopher SchreiberDirector
  • Jude UzonwanneDirector
  • Bill J. WhiteDirector
  • Joshua SilvermanDirector
  • Craig EagleDirector
  • Mitchell GlassDirector
Offering amount
$26.9M
Amount sold
$26.9M
Sales commissions
$537K
Placement agents
Palladium Capital Group, LLC, GP Nurmenkari Inc.
First sale
May 2024
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.4MofferedAug 2022 · 8 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Craig EagleDirector
  • Joshua SilvermanDirector
  • Ian RhodesExecutive Officer
  • Paul RivardExecutive Officer
  • Adam KaplinExecutive Officer
  • Chris ChapmanExecutive Officer, Director
  • Bill WhiteDirector
  • Jude UzonwanneDirector
  • Christopher SchreiberDirector
Offering amount
$7.4M
Sales commissions
$240K
Placement agents
Dawson James Securities, Inc.
First sale
Aug 2022
Incorporated
Corporation, New Jersey
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$18.1MraisedNov 2020 · 56 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Stuart BensonExecutive Officer
  • Christopher C. SchreiberExecutive Officer, Director
  • Robert C. SchroederDirector
  • Bill J. WhiteDirector
  • Joshua SilvermanDirector
Offering amount
$18.1M
Amount sold
$18.1M
Sales commissions
$1.2M
Placement agents
Katalyst Securities LLC
First sale
Nov 2020
Incorporated
Corporation, New Jersey
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedAug 2020 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher C. SchreiberExecutive Officer, Director
  • Bill J. WhiteDirector
  • Howard YeatonExecutive Officer
  • Joshua SilvermanDirector
  • Robert C. SchroederDirector
First sale
Aug 2020
Incorporated
Corporation, New Jersey
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$482.5KraisedMay 2020 · 4 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert C. SchroederDirector
  • Joshua SilvermanDirector
  • Howard YeatonExecutive Officer
  • Bill J. WhiteDirector
  • Christopher C. SchreiberExecutive Officer, Director
Offering amount
$482.5K
Amount sold
$482.5K
First sale
May 2020
Incorporated
Corporation, New Jersey
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$460KraisedApr 2020 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Howard YeatonExecutive Officer
  • Joshua SilvermanDirector
  • Christopher C. SchreiberExecutive Officer, Director
  • Bill J. WhiteDirector
  • Robert C. SchroederDirector
Offering amount
$460K
Amount sold
$460K
First sale
Apr 2020
Incorporated
Corporation, New Jersey
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Robinhood30 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

Companies competing with TNF Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Reviewing TNF Pharmaceuticals (NASDAQ:TNFA) & One Stop Systems (NASDAQ:OSS) - American Market Newsamericanbankingnews.com · Aug 2026TNF Pharmaceuticals raises $7.0M in Rule 506(b) offering | TNFA SEC Filing - Form Dstocktitan.net · Sep 2025TNF Pharmaceuticals Raises $7M in Private Placement at 44% Premium | TNFA Stock Newsstocktitan.net · Sep 2025TNF Pharmaceuticals raises $7 million in private placement at premium By Investing.cominvesting.com · Sep 2025TNF Pharmaceuticals: Strategic Financial Restructuring and Pipeline Potential Position the Company for a Major Turnaroundainvest.com · Aug 2025TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market - TNF Pharmaceuticalstnfpharma.com · Oct 2024

Frequently asked questions

What does TNF Pharmaceuticals do?
TNF Pharmaceuticals is a clinical-stage biopharma company developing therapies for autoimmune and inflammatory diseases, with lead candidates including MYMD-1, an oral TNF-alpha inhibitor, and Supera-CBD, a synthetic cannabidiol analog.
How much funding has TNF Pharmaceuticals raised?
TNF Pharmaceuticals has disclosed $71.3M raised across 8 of its 10 known rounds.
Where is TNF Pharmaceuticals headquartered?
TNF Pharmaceuticals is headquartered in New York, US.